Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 21 03:33PM ET
13.80
Dollar change
-0.08
Percentage change
-0.58
%
Index- P/E- EPS (ttm)- Insider Own38.70% Shs Outstand44.12M Perf Week-7.88%
Market Cap608.72M Forward P/E- EPS next Y-2.48 Insider Trans25.51% Shs Float27.04M Perf Month-31.36%
Income- PEG- EPS next Q-0.47 Inst Own30.37% Short Float4.91% Perf Quarter-
Sales- P/S- EPS this Y85.65% Inst Trans28.05% Short Ratio4.92 Perf Half Y-
Book/sh-3.71 P/B- EPS next Y-8.28% ROA- Short Interest1.33M Perf Year-
Cash/sh3.34 P/C4.13 EPS next 5Y44.91% ROE- 52W Range13.20 - 25.19 Perf YTD-44.80%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-45.22% Beta-
Dividend TTM- Quick Ratio14.49 Sales past 5Y0.00% Gross Margin- 52W Low4.51% ATR (14)2.01
Dividend Ex-Date- Current Ratio14.49 EPS Y/Y TTM- Oper. Margin- RSI (14)27.46 Volatility12.60% 13.57%
Employees41 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price38.50
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q- Payout- Rel Volume0.49 Prev Close13.88
Sales Surprise- EPS Surprise-164.75% Sales Q/Q- EarningsMar 20 BMO Avg Volume269.93K Price13.80
SMA20-10.84% SMA50-19.96% SMA200-19.96% Trades Volume124,516 Change-0.58%
Date Action Analyst Rating Change Price Target Change
Mar-04-25Initiated TD Cowen Buy
Mar-04-25Initiated Stifel Buy $32
Mar-04-25Initiated Guggenheim Buy $45
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TPG GP A, LLC10% OwnerFeb 10 '25Buy18.001,125,00020,250,0006,684,962Feb 12 05:21 PM
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 10 '25Buy18.001,125,00020,250,0006,923,365Feb 10 05:04 PM
ORBIMED ADVISORS LLCDirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:28 PM
Thompson Peter A.DirectorFeb 10 '25Buy18.00550,0009,900,0003,704,959Feb 10 04:05 PM
Booth BruceDirectorFeb 10 '25Buy18.0060,0001,080,000807,727Feb 10 04:05 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 10 '25Buy18.0060,0001,080,000807,727Feb 10 04:05 PM